Role of epidermal growth factor receptor in vascular structure and function

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 2, 2014, Pages 113-121

  Schreier, Barbara ^a   Gekle, Michael ^a   Grossmann, Claudia ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Atherosclerosis; Diabetes; Endothelial cells; Hypertension; Vascular smooth muscle cells

Indexed keywords

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; BLOOD VESSELS; ENDOTHELIAL CELLS; HUMANS; LIGANDS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PROTEIN KINASE INHIBITORS; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR DISEASES;

EID: 84894062402     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/01.mnh.0000441152.62943.29     Document Type: Review

References (108)

1. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141:1117-1134.
2. Burgess AW, Cho HS, Eigenbrot C, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003; 12:541-552.
3. Dreux AC, Lamb DJ, Modjtahedi H, Ferns GAA. The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis. Atherosclerosis 2006; 186:38-53.
4. Batchu SN, Korshunov VA. Novel tyrosine kinase signaling pathways: implications in vascular remodeling. Curr Opin Nephrol Hypertens 2012; 21:122-127.
5. Schreier B, Rabe S, Schneider B, et al. Loss of epidermal growth factor receptor in vascular smooth muscle cells and cardiomyocytes causes arterial hypotension and cardiac hypertrophy. Hypertension 2013; 61:333-340.
6. Lin CC, Lin WN, Cheng SE, et al. Transactivation of EGFR/PI3K/Akt involved in ATP-induced inflammatory protein expression and cell motility. J Cell Physiol 2012; 227:1628-1638.
7. Yogi A, Callera GE, Aranha AB, et al. Sphingosine-1-phosphate-induced inflammation involves receptor tyrosine kinase transactivation in vascular cells: upregulation in hypertension. Hypertension 2011; 57:809-818.
8. Fiebeler A, Luft FC. The mineralocorticoid receptor oxidative stress. Heart Failure Rev 2005; 10:47-52.
9. Sanada F, Taniyama Y, Iekushi K, et al. Negative action of hepatocyte growth factor/c-Met system on angiotensin II signaling via ligand-dependent epithelial growth factor receptor degradation mechanism in vascular smooth muscle cells. Circ Res 2009; 105:667-675.
10. Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part III: cellular and molecular clues to heart and arterial aging. Circulation 2003; 107:490-497.
11. Krug AW, Allenhofer L, Monticone R, et al. Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptordependent pathways. Hypertension 2010; 55:1476-1483.
12. Gerthoffer WT. Mechanisms of vascular smooth muscle cell migration. Circ Res 2007; 100:607-621.
13. Tu L, De Man FS, Girerd B, et al. A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents. Am J Respir Crit Care Med 2012; 186:666-676.
14. Song GJ, Leslie KL, Barrick S, et al. EBP50 promotes focal adhesion turnover and vascular smooth muscle cells migration. J Mol Cell Cardiol 2012; 53:809-819.
15. Shafi S, Lamb D, Modjtahedi H, Ferns G. Periadventitial delivery of anti-EGF receptor antibody inhibits neointimal macrophage accumulation after angioplasty in a hypercholesterolaemic rabbit. Int J Exp Pathol 2010; 91:224-234.
16. Bakken AM, Protack CD, Roztocil E, et al. Cell migration in response to the amino-terminal fragment of urokinase requires epidermal growth factor receptor activation through an ADAM-mediated mechanism. J Vasc Surg 2009; 49:1296-1303.
17. Takaguri A, Shirai H, Kimura K, et al. Caveolin-1 negatively regulates a metalloprotease-dependent epidermal growth factor receptor transactivation by angiotensin II. J Mol Cell Cardiol 2011; 50:545-551.
18. Shimizu H, Hirose Y, Goto S, et al. Indoxyl sulfate enhances angiotensin II signaling through upregulation of epidermal growth factor receptor expression in vascular smooth muscle cells. Life Sci 2012; 91 (5-6):172-177.
19. Sakurada T, Ishizawa K, Imanishi M, et al. Nitrosonifedipine ameliorates angiotensin II-induced vascular remodeling via antioxidative effects. Naunyn Schmiedebergs Arch Pharmacol 2013; 386:29-39.
20. Mugabe BE, Yaghini FA, Song CY, et al. Angiotensin II-induced migration of vascular smooth muscle cells is mediated by p38 mitogen-activated protein kinase-activated c-Src through spleen tyrosine kinase and epidermal growth factor receptor transactivation. J Pharmacol Exp Ther 2010; 332:116-124.
21. Duru EA, Fu Y, Davies MG. Urokinase requires NAD(P)H oxidase to transactivate the epidermal growth factor receptor. Surgery 2012; 152:879-885.
22. Wang D, Paria BC, Zhang Q, et al. A role for Gab1/SHP2 in thrombin activation of PAK1: gene transfer of kinase-dead PAK1 inhibits injury-induced restenosis. Circ Res 2009; 104:1066-1075.
23. Singh NK, Wang D, Kundumani-Sridharan V, et al. 15-Lipoxygenase-1- enhanced Src-Janus kinase 2-signal transducer and activator of transcription 3 stimulation and monocyte chemoattractant protein-1 expression require redox-sensitive activation of epidermal growth factor receptor in vascular wall remodeling. J Biol Chem 2011; 286:22478-22488.
24. Jagadeesha DK, Takapoo M, Banfi B, et al. Nox1 transactivation of epidermal growth factor receptor promotes N-cadherin shedding and smooth muscle cell migration. Cardiovasc Res 2012; 93:406-413.
25. Suc I, Meilhac O, Lajoie-mazenc I, et al. Activation of EGF receptor by oxidized LDL. FASEB J 1998; 12:665-671.
26. Liao PL, Cheng YW, Li CH, et al. 7-Ketocholesterol and cholesterol-5alpha, 6alpha-epoxide induce smooth muscle cell migration and proliferation through the epidermal growth factor receptor/phosphoinositide 3-kinase/Akt signaling pathways. Toxicol Lett 2010; 197:88-96.
27. Gekle M, Mildenberger S, Freudinger R, Grossmann C. Altered collagen homeostasis in human aortic smooth muscle cells (HAoSMCs) induced by aldosterone. Pfluegers Archiv Eur J Physiol 2007; 454:403-413.
28. Grossmann C, Krug AW, Freudinger R, et al. Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter. Am J Physiol Endocrinol Metab 2007; 292:E1790-E1800.
29. Letavernier E, Perez J, Bellocq A, et al. Targeting the calpain/calpastatin system as a new strategy to prevent cardiovascular remodeling in angiotensin II-induced hypertension. Circ Res 2008; 102:720-728.
30. Schreier B, Rabe S, Schneider B, et al. Aldosterone/NaCl-induced renal and cardiac fibrosis is modulated by TGF-[beta] responsiveness of T cells. Hypertens Res 2011; 34:623-629.
31. Rayego-Mateos S, Rodrigues-Diez R, Morgado-Pascual JL, et al. Connective tissue growth factor is a new ligand of epidermal growth factor receptor. J Mol Cell Biol 2013; 5:323-335.
32. Andrianifahanana M, Wilkes MC, Gupta SK, et al. Profibrotic TGF beta responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases. FASEB J 2013; 27:4444-4454.
33. Samarakoon R, Dobberfuhl AD, Cooley C, et al. Induction of renal fibrotic genes by TGF-beta1 requires EGFR activation, p53 and reactive oxygen species. Cell Signall 2013; 25:2198-2209.
34. Karashima T, Sweeney P, Slaton JW, et al. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgenindependent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 2002; 8:1253-1264.
35. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000; 6:2166-2174.
36. Repertinger SK, Campagnaro E, Fuhrman J, et al. EGFR enhances early healing after cutaneous incisional wounding. J Investig Dermatol 2004; 123:982-989.
37. Casanova ML, Larcher F, Casanova B, et al. A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res 2002; 62:3402-3407.
38. Michaelis UR, Fisslthaler B, Medhora M, et al. Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor. FASEB J 2003; 17:770-772.
39. LaRusch GA, Mahdi F, Shariat-Madar Z, et al. Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis. Blood 2010; 115:5111-5120.
40. McMellen ME, Wakeman D, Erwin CR, et al. Epidermal growth factor receptor signaling modulates chemokine (CXC) ligand 5 expression and is associated with villus angiogenesis after small bowel resection. Surgery 2010; 148:364-370.
41. Buharalioglu C, Song C, Yaghini F, et al. Angiotensin II-induced process of angiogenesis is mediated by spleen tyrosine kinase via VEGF receptor-1 phosphorylation. Am J Physiol Heart Circ Physiol 2011; 301:H1043-H1055.
42. Tai SC, Robb GB, Marsden PA. Endothelial nitric oxide synthase: a new paradigm for gene regulation in the injured blood vessel. Arterioscler Thromb Vasc Biol 2004; 24:405-412.
43. Klinge CM, Blankenship KA, Risinger KE, et al. Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells. J Biol Chem 2005; 280:7460-7468.
44. Yang YM, Huang A, Kaley G, Sun D. eNOS uncoupling and endothelial dysfunction in aged vessels. Am J Physiol Heart Circ Physiol 2009; 297:H1829-H1836.
45. Nagata D, Takahashi M, Sawai K, et al. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 2006; 48:165-171.
46. Oak JH, Cai H. Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice. Diabetes 2007; 56:118-126.
47. Cheng J, Garcia V, Ding Y, et al. Induction of angiotensin-converting enzyme and activation of the renin angiotensin system contribute to 20-hydroxyeicosatetraenoic acid-mediated endothelial dysfunction. Arterioscler Thromb Vasc Biol 2012; 32:1917-1924.
48. Sugiyama T, Yoshimoto T, Tsuchiya K, et al. Aldosterone induces angiotensin converting enzyme (ACE) gene expression via JAK2-dependent pathway in rat endothelial cells. Endocrinology 2005; 146:3900-3906.
49. Limas C, Westrum B, Limas CJ. The evolution of vascular changes in the spontaneously hypertensive rat. Am J Pathol 1980; 98:357-384.
50. Li Y, Levesque LO, Anand-Srivastava MB. Epidermal growth factor receptor transactivation by endogenous vasoactive peptides contributes to hyperproliferation of vascular smooth muscle cells of SHR. Am J Physiol Heart Circ Physiol 2010; 299:H1959-H1967.
51. Sandoval YHG, Li Y, Anand-Srivastava MB. Transactivation of epidermal growth factor receptor by enhanced levels of endogenous angiotensin II contributes to the overexpression of Gialpha proteins in vascular smooth muscle cells from SHR. Cell Signall 2011; 23:1716-1726.
52. Francois H, Placier S, Flamant M, et al. Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J 2004; 18:926-928.
53. Griol-Charhbili V, Fassot C, Messaoudi S, et al. Epidermal growth factor receptor mediates the vascular dysfunction but not the remodeling induced by aldosterone/salt. Hypertension 2011; 57:238-244.
54. Schreier B, Doehler M, Rabe S, et al. Consequences of epidermal growth factor receptor (ErbB1) loss for vascular smooth muscle cells from mice with targeted deletion of ErbB1. Arterioscler Thromb Vasc Biol 2011; 31:1643-1652.
55. Threadgill DW, Dlugosz AA, Hansen LA, et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 1995; 269:230-234.
56. Gao P, Wang XM, Qian DH, et al. Induction of oxidative stress by oxidized LDL via meprin alpha-activated epidermal growth factor receptor in macrophages. Cardiovasc Res 2013; 97:533-543.
57. Stanic B, Pandey D, Fulton DJ, Miller FJ. Increased epidermal growth factor-like ligands are associated with elevated vascular nicotinamide adenine dinucleotide phosphate oxidase in a primate model of atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32:2452-2460.
58. Miyagawa J, Higashiyama S, Kawata S, et al. Localization of heparin-binding EGF-like growth factor in the smooth muscle cells and macrophages of human atherosclerotic plaques. J Clin Invest 1995; 95:404-411.
59. Lee S, Springstead JR, Parks BW, et al. Metalloproteinase processing of HBEGF is a proximal event in the response of human aortic endothelial cells to oxidized phospholipids. Arterioscler Thromb Vasc Biol 2012; 32:1246-1254.
60. Osada-Oka M, Kita H, Yagi S, et al. Angiotensin AT1 receptor blockers suppress oxidized low-density lipoprotein-derived formation of foam cells. Eur J Pharmacol 2012; 679 (1-3):9-15.
61. Schraufstatter IU, Zhao M, Khaldoyanidi SK, Discipio RG. The chemokine CCL18 causes maturation of cultured monocytes to macrophages in the M2 spectrum. Immunology 2012; 135:287-298.
62. Gamou S, Shimizu N. Hydrogen peroxide preferentially enhances the tyrosine phosphorylation of epidermal growth factor receptor. FEBS Lett 1995; 357:161-164.
63. Sachsenmaier C, Radler-Pohl A, Zinck R, et al. Involvement of growth factor receptors in the mammalian UVC response. Cell 1994; 78:963-972.
64. Chen K, Vita JA, Berk BC, Keaney JF. c-Jun N-terminal kinase activation by hydrogen peroxide in endothelial cells involves Src-dependent epidermal growth factor receptor transactivation. J Biol Chem 2001; 276:16045-16050.
65. Hsieh H, Lin C, Chan H, Yang C. c-Src-dependent EGF receptor transactivation contributes to ET-1-induced COX-2 expression in brain microvascular endothelial cells. J Neurinflammation 2012; 9:152.
66. Hsieh HL, Tung WH, Wu CY, et al. Thrombin induces EGF receptor expression and cell proliferation via a PKC(delta)/c-Src-dependent pathway in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2009; 29:1594-1601.
67. Fukuda D, Enomoto S, Hirata Y, et al. The angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice. Biomed Pharmacother 2010; 64:712-717.
68. Fries DM, Penha RG, Damico EA, et al. Oxidized low-density lipoprotein stimulates nitric oxide release by rabbit aortic endothelial cells. Biochem Biophys Res Comm 1995; 207:231-237.
69. Wong MM, Winkler B, Karamariti E, et al. Sirolimus stimulates vascular stem/ progenitor cell migration and differentiation into smooth muscle cells via epidermal growth factor receptor/extracellular signal-regulated kinase/betacatenin signaling pathway. Arterioscler Thromb Vasc Biol 2013; 33:2397-2406.
70. Templeton A, Braendle M, Cerny T, Gillessen S. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol 2008; 19:824-825.
71. Costa DB, Huberman MS. Improvement of type 2 diabetes in a lung cancer patient treated with erlotinib. Diabetes Care 2006; 29:1711.
72. Veneri D, Franchini M, Bonora E. Imatinib and regression of type 2 diabetes. N Engl J Med 2005; 352:1049-1050.
73. Benter IF, Benboubetra M, Hollins A J, et al. Early inhibition of EGFR signaling prevents diabetes-induced up-regulation of multiple gene pathways in the mesenteric vasculature. Vasc Pharmacol 2009; 51:236-245.
74. Nagareddy PR, MacLeod KM, McNeill JH. GPCR agonist-induced transactivation of the EGFR upregulates MLC II expression and promotes hypertension in insulin-resistant rats. Cardiovasc Res 2010; 87:177-186.
75. Belmadani S, Palen DI, Gonzalez-Villalobos RA, et al. Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice. Diabetes 2008; 57:1629-1637.
76. Konishi A, Berk BC. Epidermal growth factor receptor transactivation is regulated by glucose in vascular smooth muscle cells. J Biol Chem 2003; 278:35049-35056.
77. Descorbeth M, Anand-Srivastava MB. Role of growth factor receptor transactivation in high glucose-induced increased levels of Gq/11alpha and signaling in vascular smooth muscle cells. J Mol Cell Cardiol 2010; 49:221-233.
78. Prada PO, Ropelle ER, Mourao RH, et al. EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat dietfed mice. Diabetes 2009; 58:2910-2919.
79. Cai W, Torreggiani M, Zhu L, et al. AGER1 regulates endothelial cell NADPH oxidase-dependent oxidant stress via PKC-delta: implications for vascular disease. Am J Physiol Cell Physiol 2010; 298:C624-C634.
80. Cai W, He JC, Zhu L, et al. Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci 2006; 103:13801-13806.
81. Jamroz-Wisniewska A, Wojcicka G, Lowicka E, et al. Transactivation of epidermal growth factor receptor in vascular and renal systems in rats with experimental hyperleptinemia: role in leptin-induced hypertension. Biochem Pharmacol 2008; 75:1623-1638.
82. Benter IF, Yousif MHM, Hollins AJ, et al. Diabetes-induced renal vascular dysfunction is normalized by inhibition of epidermal growth factor receptor tyrosine kinase. J Vasc Res 2005; 42:284-291.
83. Galan RG, Kassan M, Choi SK, et al. A novel role for epidermal growth factor receptor tyrosine kinase and its downstream endoplasmic reticulum stress in cardiac damage and microvascular dysfunction in type 1 diabetes mellitus. Hypertension 2012; 60:71-80.
84. Yousif MHM, Benter IF, Dunn KMJ, et al. Role of 20- hydroxyeicosatetraenoic acid in altering vascular reactivity in diabetes. Auton Autacoid Pharmacol 2009; 29 (1-2):1-12.
85. Akhtar S, Yousif MHM, Dhaunsi GS, et al. Activation of ErbB2 and downstream signalling via Rho kinases and ERK1/2 contributes to diabetesinduced vascular dysfunction. PLoS One 2013; 8:e67813.
86. Palen DI, Matrougui K. Role of elevated EGFR phosphorylation in the induction of structural remodelling and altered mechanical properties of resistance artery from type 2 diabetic mice. Diabetes Metab Res Rev 2008; 24:651-656.
87. Choi SK, Galan M, Partyka M, et al. Chronic inhibition of epidermal growth factor receptor tyrosine kinase and extracellular signal-regulated kinases 1 and 2 (ERK1/2) augments vascular response to limb ischemia in type 2 diabetic mice. Am J Pathol 2012; 180:410-418.
88. Berk BC, Brock TA, Webb RC, et al. Epidermal growth factor, a vascular smooth muscle mitogen, induces rat aortic contraction. J Clin Invest 1985; 75:1083-1086.
89. Florian JA, Watts SW. Epidermal growth factor: a potent vasoconstrictor in experimental hypertension. Am J Physiol 1999; 276:H976-H983.
90. Keiser JA, Ryan MJ. Hemodynamic effects of epidermal growth factor in conscious rats and monkeys. Proc Natl Acad Sci 1996; 93:4957-4961.
91. Zhou Y, Brigstock D, Besner GE. Heparin-binding EGF-like growth factor is a potent dilator of terminal mesenteric arterioles.Microvasc Res. 2009;78:78-85.
92. McEwen ST, Balus SF, Durand MJ, Lombard JH. Angiotensin II maintains cerebral vascular relaxation via EGF receptor transactivation and ERK1/2. Am J Physiol Heart Circ Physiol 2009; 297:H1296-H1303.
93. Yousif MHM, Benter IF, Akhtar S. The role of tyrosine kinase-mediated pathways in diabetes-induced alterations in responsiveness of rat carotid artery. Auton Autacoid Pharmacol 2005; 25:69-78.
94. Flamant M, Tharaux PL, Placier S, et al. Epidermal growth factor receptor transactivation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J 2003; 17:327-329.
95. Kagiyama S, Eguchi S, Frank GD, et al. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation 2002; 106:909-912.
96. Ulu N, Gurdal H, Landheer SW, et al. Alpha1-Adrenoceptor-mediated contraction of rat aorta is partly mediated via transactivation of the epidermal growth factor receptor. Brit J Pharmacol 2010; 161:1301-1310.
97. Montani D, Chaumais MC, Guignabert C, et al. Targeted therapies in pulmonary arterial hypertension. Pharmacol Ther 2013. [Epub ahead of print]
98. Norton C, Broughton B, Jernigan N, et al. Enhanced depolarization-induced pulmonary vasoconstriction following chronic hypoxia requires EGFR-dependent activation of NAD(P)H oxidase. Antioxid Redox Signal 2013; 18:1777-1788.
99. Izikki M, Mercier O, Lecerf F, et al. The beneficial effect of suramin on monocrotaline-induced pulmonary hypertension in rats. PLoS One 2013; 8:e77073.
100. Merklinger SL, Jones PL, Martinez EC, Rabinovitch M. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 2005; 112:423-431.
101. Dahal BK, Cornitescu T, Tretyn A, et al. Role of epidermal growth factor inhibition in experimental pulmonary hypertension. Am J Respir Crit Care Med 2010; 181:158-167.
102. Schultz K, Fanburg B, Beasley D. Hypoxia and hypoxia-inducible factor-1alpha promote growth factor-induced proliferation of human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2006; 290: H2528-H2534.
103. Nelin LD, Chicoine LG, Reber KM, et al. Cytokine-induced endothelial arginase expression is dependent on epidermal growth factor receptor. Am J Respir Cell Mol Biol 2005; 33:394-401.
104. Toby IT, Chicoine LG, Cui H, et al. Hypoxia-induced proliferation of human pulmonary microvascular endothelial cells depends on epidermal growth factor receptor tyrosine kinase activation. Am J Physiol Lung Cell Mol Physiol 2010; 298:L600-L606.
105. Janakidevi K, Fisher M, Del Vecchio P, et al. Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells. Am J Physiol 1992; 263 (6 Pt 1):C1295-C1301.
106. Lee KS, Park JH, Lee S, et al. HB-EGF induces delayed STAT3 activation via NF-KB mediated IL-6 secretion in vascular smooth muscle cell. Biochim Biophys Acta 2007; 1773:1637-1644.
107. Robitaille G, Christin MS, Clement I, et al. Nuclear autoantigen CENP-B transactivation of the epidermal growth factor receptor via chemokine receptor 3 in vascular smooth muscle cells. Arthritis Rheum 2009; 60:2805-2816.
108. Garg P, Yang S, Liu A, et al. Thrombospondin-1 opens the paracellular pathway in pulmonary microvascular endothelia through EGFR/ErbB2 activation. Am J Physiol Lung Cell Mol Physiol 2011; 301:L79-L90.